Solid Tumors and Metastatic LesionsMRgRTNCT02701712
Receiving Radiation Therapy in the MRgRT Research Facility
A study testing Magnetic resonance - guided radiation therapy (MRgRT) in people with Solid Tumors and Metastatic Lesions, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
The aim of this study is to evaluate the technical performance of magnetic-resonance guided radiotherapy (MRgRT) facility at the Princess Margaret Cancer Centre and the impact on the workflow of the clinical team in this facility. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Solid Tumors and Metastatic Lesions
- What is being tested?
- Magnetic resonance - guided radiation therapy (MRgRT)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteCanada
- Study dates
- Feb 2016to Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Ability to provide informed consent
- Planned to receive clinical intervention (imaging or treatment) in the MRgRT facility
- At least 18 years of age
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this study is to evaluate the technical performance of magnetic-resonance guided radiotherapy (MRgRT) facility at the Princess Margaret Cancer Centre and the impact on the workflow of the clinical team in this facility.
- Conditions
- Solid Tumors and Metastatic Lesions
- Being tested
- Magnetic resonance - guided radiation therapy (MRgRT)
- Keywords
- magnetic resonance, external beam radiotherapy, brachytherapy, radiotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic resonance - guided radiation therapy (MRgRT)Radiation
Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
| Study group | Role | What they receive |
|---|---|---|
| Magnetic resonance - guided radiation therapy (MRgRT) | Experimental | Magnetic resonance (MR) - guided radiation therapy Receives: Radiation: Magnetic resonance - guided radiation therapy (MRgRT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of planned patients receiving treatment in the MRgRT facility
Measured: 2 years
Secondary outcomes (1)
Measure tumor size before, during and after radiotherapy
Collect and analyze imaging data before, during and after radiotherapy, and the related treatment data
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Mar 2016 (estimated)
- Study startFeb 2016
- Primary completionFeb 2027 (estimated)
- Study completionFeb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Solid Tumors and Metastatic LesionsStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael Milosevic, MD, Principal investigator, University Health Network, Toronto
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02701712
- Sponsor's protocol ID
- 14-8210-CE
- Acronym
- MRgRT
- Status last verified
- Mar 2026
- First submitted
- 22 Feb 2016
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Receiving Radiation Therapy in the MRgRT Research Facility
- ClinicalTrials.gov ID
- NCT02701712
- Acronym / sponsor ID
- MRgRT / 14-8210-CE
- Conditions
- Solid Tumors and Metastatic Lesions
- Keywords
- magnetic resonance, external beam radiotherapy, brachytherapy, radiotherapy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Study start
- Feb 2016 (actual)
- Primary completion
- Feb 2027 (estimated)
- Study completion
- Feb 2027 (estimated)
- First posted
- 8 Mar 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to evaluate the technical performance of magnetic-resonance guided radiotherapy (MRgRT) facility at the Princess Margaret Cancer Centre and the impact on the workflow of the clinical team in this facility.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Magnetic resonance - guided radiation therapy (MRgRT) | Experimental | Radiation: Magnetic resonance - guided radiation therapy (MRgRT)Magnetic resonance (MR) - guided radiation therapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Ability to provide informed consent
- Planned to receive clinical intervention (imaging or treatment) in the MRgRT facility
- At least 18 years of age
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic resonance - guided radiation therapy (MRgRT)Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients | Radiation | Magnetic resonance - guided radiation therapy (MRgRT) |
Primary outcome
Proportion of planned patients receiving treatment in the MRgRT facility
Time frame: 2 years
1 secondary outcome
Measure tumor size before, during and after radiotherapy
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
Related trials for Solid Tumors and Metastatic Lesions
RecruitingPhase 3
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm
RecruitingPhase 2
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Brain Metastases, Adult, Brain Tumor - Metastatic
Recruiting
Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Advanced Solid Tumor, Metastatic Cancer
Not yet recruitingPhase 2
Lesion-Allocated Therapy for Multiple Metastases and Tumor-Zoned Treatment for Bulky Tumors: A Phase II Study of Iodine-125 Seed Implantation Combined With Cryoablation in High-Burden Metastatic Disease
High-Burden Metastatic Solid Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Milosevic, MD principal investigator
University Health Network, Toronto
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magnetic resonance - guided radiation therapy (MRgRT) in people with Solid Tumors and Metastatic Lesions, run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of planned patients receiving treatment in the MRgRT facility (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.